Arnold M, Karim-Kos HE, Coebergh JW, Byrnes G, Antilla A, Ferlay J, et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. Eur J Cancer (Oxf, Engl: 1990). 2015;51:1164–87.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.
Rouvière O, Schoots IG, Mottet N. Multiparametric magnetic resonance imaging before prostate biopsy: a chain is only as strong as its weakest link. Eur Urol. 2019;75:889–90.
Kalapara AA, Nzenza T, Pan HYC, Ballok Z, Ramdave S, O’Sullivan R, et al. Detection and localisation of primary prostate cancer using (68) gallium prostate-specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology. BJU Int. 2020;126:83–90.
CAS PubMed Article Google Scholar
Borghesi M, Ahmed H, Nam R, Schaeffer E, Schiavina R, Taneja S, et al. Complications after systematic, random, and image-guided prostate biopsy. Eur Urol. 2017;71:353–65.
Carroll PR. Prostate biopsy: a wealth of information when done and interpreted correctly. J Clin Oncol. 2000;18:1161–3.
CAS PubMed Article Google Scholar
Rosenkrantz AB, Verma S, Choyke P, Eberhardt SC, Eggener SE, Gaitonde K, et al. Prostate magnetic resonance imaging and magnetic resonance imaging targeted biopsy in patients with a prior negative biopsy: a consensus statement by AUA and SAR. J Urol. 2016;196:1613–8.
PubMed PubMed Central Article Google Scholar
Team NGU National Institute for Health and Care Excellence: Clinical Guidelines. In: Prostate cancer: diagnosis and management. National Institute for Health and Care Excellence (UK) Copyright (c) NICE 2019: London, 2019.
Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79:243–62.
CAS PubMed Article Google Scholar
Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol. 2011;186:1830–4.
Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol. 2010;183:963–8.
Elkhoury FF, Felker ER, Kwan L, Sisk AE, Delfin M, Natarajan S, et al. Comparison of targeted vs systematic prostate biopsy in men who are biopsy naive: the prospective assessment of image registration in the diagnosis of prostate cancer (PAIREDCAP) study. JAMA Surg. 2019;154:811–8.
PubMed PubMed Central Article Google Scholar
Padhani AR, Weinreb J, Rosenkrantz AB, Villeirs G, Turkbey B, Barentsz J. Prostate imaging-reporting and data system steering committee: PI-RADS v2 status update and future directions. Eur Urol. 2019;75:385–96.
Mottet N. Guideline Prostate Cancer. European Association of Urology EAU 2019.
De Visschere P, Oosterlinck W, De Meerleer G, Villeirs G. Clinical and imaging tools in the early diagnosis of prostate cancer, a review. JBR-BTR. 2010;93:62–70.
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF). Interdisziplinäre S3-Leitlinie zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Version 5.1 - Mai 2019. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): http://www.leitlinienprogramm-onkolo-gie.de/leitlinien/prostatakarzinom/, 2019.
Presti JC. Prostate biopsy: current status and limitations. Rev Urol. 2007;9:93–8.
PubMed PubMed Central Google Scholar
Bjurlin MA, Wysock JS, Taneja SS. Optimization of prostate biopsy: review of technique and complications. Urol Clin North Am. 2014;41:299–313.
PubMed PubMed Central Article Google Scholar
Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol. 2006;175:1605–12.
Litwin MS, Tan H-J. The diagnosis and treatment of prostate cancer: a review. JAMA. 2017;317:2532–42.
Das CJ, Razik A, Sharma S, Verma S. Prostate biopsy: when and how to perform. Clin Radio. 2019;74:853–64.
Hou Y, Jiang KW, Zhang J, Bao ML, Shi HB, Qu JR, et al. A clinical available decision support scheme for optimizing prostate biopsy based on mpMRI. Prostate Cancer Prostatic Dis. 2022 https://doi.org/10.1038/s41391-021-00489-z.
Russo F, Regge D, Armando E, Giannini V, Vignati A, Mazzetti S, et al. Detection of prostate cancer index lesions with multiparametric magnetic resonance imaging (mp-MRI) using whole-mount histological sections as the reference standard. BJU Int. 2016;118:84–94.
Karavitakis M, Winkler M, Abel P, Livni N, Beckley I, Ahmed HU. Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy. Prostate Cancer Prostatic Dis. 2011;14:46–52.
CAS PubMed Article Google Scholar
Rais-Bahrami S, Türkbey B, Rastinehad AR, Walton-Diaz A, Hoang AN, Siddiqui MM, et al. Natural history of small index lesions suspicious for prostate cancer on multiparametric MRI: recommendations for interval imaging follow-up. Diagn Inter Radio. 2014;20:293–298.
Maccagnano C, Gallina A, Roscigno M, Raber M, Capitanio U, Saccà A, et al. Prostate saturation biopsy following a first negative biopsy: state of the art. Urol Int. 2012;89:126–135.
CAS PubMed Article Google Scholar
Barkovich EJ, Shankar PR, Westphalen AC. A systematic review of the existing prostate imaging reporting and data system version 2 (PI-RADSv2) literature and subset meta-analysis of PI-RADSv2 categories stratified by gleason scores. AJR Am J Roentgenol. 2019;212:847–54.
Tracy CR, Flynn KJ, Sjoberg DD, Gellhaus PT, Metz CM, Ehdaie B. Optimizing MRI-targeted prostate biopsy: the diagnostic benefit of additional targeted biopsy cores. Urologic Oncol. 2021;39:193.e191–193.e196.
van der Leest M, Cornel E, Israël B, Hendriks R, Padhani AR, Hoogenboom M, et al. Head-to-head comparison of transrectal ultrasound-guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-naïve men with elevated prostate-specific antigen: a large prospective multicenter clinical study. Eur Urol. 2019;75:570–8.
Mazzone E, Stabile A, Pellegrino F, Basile G, Cignoli D, Cirulli GO, et al. Positive predictive value of prostate imaging reporting and data system version 2 for the detection of clinically significant prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol. 2021;4:697–713.
Diamand R, Oderda M, Al Hajj Obeid W, Albisinni S, Van Velthoven R, Fasolis G, et al. A multicentric study on accurate grading of prostate cancer with systematic and MRI/US fusion targeted biopsies: comparison with final histopathology after radical prostatectomy. World J Urol. 2019;37:2109–17.
CAS PubMed Article Google Scholar
Bryk DJ, Llukani E, Taneja SS, Rosenkrantz AB, Huang WC, Lepor H. The role of ipsilateral and contralateral transrectal ultrasound-guided systematic prostate biopsy in men with unilateral magnetic resonance imaging lesion undergoing magnetic resonance imaging-ultrasound fusion-targeted prostate biopsy. Urology. 2017;102:178–82.
Zhang M, Milot L, Khalvati F, Sugar L, Downes M, Baig SM, et al. Value of increasing biopsy cores per target with cognitive MRI-targeted transrectal US prostate biopsy. Radiology. 2019;291:83–9.
Lu AJ, Syed JS, Ghabili K, Hsiang WR, Nguyen KA, Leapman MS, et al. Role of core number and location in targeted magnetic resonance imaging-ultrasound fusion prostate biopsy. Eur Urol. 2019;76:14–7.
Calio BP, Sidana A, Sugano D, Gaur S, Maruf M, Jain AL, et al. Risk of upgrading from prostate biopsy to radical prostatectomy pathology-does saturation biopsy of index lesion during multiparametric magnetic resonance imaging-transrectal ultrasound fusion biopsy help? J Urol. 2018;199:976–82.
PubMed PubMed Central Article Google Scholar
Kenigsberg AP, Renson A, Rosenkrantz AB, Huang R, Wysock JS, Taneja SS, et al. Optimizing the number of cores targeted during prostate magnetic resonance imaging fusion target biopsy. Eur Urol Oncol. 2018;1:418–25.
Dimitroulis P, Rabenalt R, Nini A, Hiester A, Esposito I, Schimmöller L, et al. Multiparametric magnetic resonance imaging/ultrasound fusion prostate biopsy-are 2 biopsy cores per magnetic resonance imaging lesion required? J Urol. 2018;200:1030–4.
Calio BP, Deshmukh S, Mitchell D, Roth CG, Calvaresi AE, Hookim K, et al. Spatial distribution of biopsy cores and the detection of intra-lesion pathologic heterogeneity. Ther Adv Urol. 2019;11:1756287219842485.
CAS PubMed PubMed Central Article Google Scholar
Deo RC. Machine learning in medicine. Circulation. 2015;132:1920–30.
PubMed PubMed Central Article Google Scholar
de Rooij M, Israël B, Tummers M, Ahmed HU, Barrett T, Giganti F, et al. ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists’ training. Eur Radiol. 2020;30:5404–16.
PubMed PubMed Central Article Google Scholar
Wasserman L. All of statistics: a concise course in statistical inference. Springer Texts in Statistics 2004;26.
Hayfield T, Racine JS. Nonparametric econometrics: the np package. J Stat Softw. 2008;27:1–32.
Meyer D, Dimitriadou E, Hornik K, Weingessel A, Leisch F, Chang C et al. Package ‘e1071’. The R Journal 2019.
EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2020, 2020.
Bootsma AM, Laguna Pes MP, Geerlings SE, Goossens A. Antibiotic prophylaxis in urologic procedures: a systematic review. Eur Urol. 2008;54:1270–86.
留言 (0)